Altimmune, Inc. (NASDAQ:ALT) Receives $16.83 Consensus Target Price from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $16.8333.

Several research analysts have issued reports on ALT shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Monday, October 20th. Citizens Jmp decreased their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Monday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th.

Insider Transactions at Altimmune

In other Altimmune news, Director Jerome Benedict Durso bought 12,500 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the transaction, the director directly owned 12,500 shares in the company, valued at approximately $51,625. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Gill bought 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average cost of $4.10 per share, with a total value of $51,250.00. Following the purchase, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 4.40% of the stock is owned by insiders.

Institutional Trading of Altimmune

Several hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new position in Altimmune during the third quarter worth about $38,000. BNP Paribas Financial Markets lifted its holdings in shares of Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after acquiring an additional 5,253 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in Altimmune during the second quarter worth about $40,000. Prudential Financial Inc. bought a new stake in Altimmune in the 2nd quarter worth approximately $43,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Altimmune in the 3rd quarter valued at $46,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Stock Up 0.1%

Shares of ALT opened at $4.01 on Tuesday. The stock’s 50-day moving average price is $4.52 and its two-hundred day moving average price is $4.37. Altimmune has a 12 month low of $2.90 and a 12 month high of $8.05. The company has a market capitalization of $417.88 million, a PE ratio of -3.74 and a beta of -0.03. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. On average, analysts anticipate that Altimmune will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.